Skip to main content
Revista da Associação Médica Brasileira logoLink to Revista da Associação Médica Brasileira
. 2023 Aug 4;69(Suppl 1):e2023S109. doi: 10.1590/1806-9282.2023S109

Update on specific dermatoses of pregnancy

Maria de Lourdes Ribeiro de Carvalho 1, Geraldo Magela Magalhães 2, Henrique Vitor Leite 3
PMCID: PMC10411713  PMID: 37556628

INTRODUCTION

During pregnancy, changes in the immune, metabolic, endocrine, and vascular systems 1,2 can induce skin changes of three natures: (a) the physiological changes of pregnancy, (b) dermatoses and tumors influenced and/or aggravated by pregnancy, and (c) specific dermatoses of pregnancy (SDP) 3,4 . This review will address SDP, which constitutes a heterogeneous group of inflammatory dermatoses of unknown etiology, highly pruritic, and occurring during the immediate pregnancy-puerperal cycle 5 . Until 1982/1983, the nomenclature of these dermatoses was quite confusing. In 1982, Holmes et al. proposed a classification into four major groups: polymorphic eruption of pregnancy (PEP), pemphigoid gestationis (PG), pruritic folliculitis of pregnancy (PFP), and prurigo of pregnancy (PP) 6,7 . In 2006, Ambros-Rudolph et al. grouped PFP and PP into a group called atopic eruption of pregnancy (AEP). Furthermore, they included intrahepatic cholestasis of pregnancy (IHCP) in the SDP group 8 . AEP can be considered another specific dermatosis. However, several authors propose that PFP and PP continue to be contemplated until further studies are conducted to clarify this heterogeneous group of dermatoses 913 . Table 1 summarizes the SDP reviewed in this article.

Table 1. Specific dermatoses of pregnancy, according to the reclassification by Ambros-Rudolph et al. 8 .

Polymorphic eruption of pregnancy (PEP) Pemphigoid gestationis (PG) Atopic eruption of pregnancy (AEP) Intrahepatic cholestasis of pregnancy (IHCP)
Frequency Frequent Rare Frequent Variable, according to geographic region and ethnic origin
Onset Third trimester. Rare in the postpartum Second/third trimester Rare in the postpartum First/second trimester Second/third trimester
Clinical feature Urticarial papules with initial lesions in the striae, sparing the periumbilical region Vesicobullous and urticarial lesions with periumbilical involvement Eczematous lesions (AEP), monomorphic papules followed by pustules on the trunk (PFP), and papules and nodules on the extensor surfaces of the limbs and trunk (PP). No primary skin lesion. Excoriations and/or prurigo due to scratching
Diagnosis Clinical diagnosis Tests for differential diagnosis when necessary DIF-deposit C3 BMZ IIF-anti-BMZ antibodies outlining the roof of the skin (salt-split technique) Clinical diagnosis Elevated serum levels of IgE Laboratory Increased bile acids, altered liver function, after ruling out other liver diseases
Fetal risk No Yes No Yes
Recurrence No Yes, including the use of oral contraceptives Variable Yes, including the use of oral contraceptives

DIF: direct immunofluorescence; IIF: indirect immunofluorescence; BMZ: basement membrane zone; PFP: pruritic folliculitis of pregnancy; PP: prurigo of pregnancy.

POLYMORPHIC ERUPTION OF PREGNANCY

PEP has an unknown etiology. It is benign and self-limited, occurring at the end of pregnancy (between the 36th and 39th weeks) and, rarely, in the immediate puerperium 14 . The term PEP is preferred over previously used names, such as toxemic rash of pregnancy, erythema toxicum of pregnancy, erythema multiforme of pregnancy, and pruritic urticarial papules and plaques of pregnancy (PUPPP) 1,15 , because this denomination encompasses all the clinical and morphological alterations involving this dermatosis 7,16,17 .

It is considered the most frequent SDP 2 , with an estimated incidence of 1:200 pregnancies, the vast majority occurring in primigravidae 2,7 . The suggested pathophysiology, although not yet elucidated 1 , is related to an inflammatory process triggered by rapid abdominal distention, which may explain the association with excessive weight gain, twin pregnancy, and a large fetus for gestational age 4,8,18 . Recently, the authors have suggested that the immune mechanism of the upregulated Th2 cytokine profile, including IL-9 and IL-33, and the reaction against bacteria and fungi residing in the skin, may be involved 16 . A study of 517 in vitro fertilization (IVF) pregnancies and 1,253 spontaneous pregnancies concluded that PEP was statistically more frequent in pregnancies resulting from IVF than in spontaneous pregnancies. Also, it was suggested that prolonged treatment with progesterone might be related to a higher frequency of PEP 19 .

The typical clinical feature begins with urticarial papules located along the abdominal striae, always sparing the periumbilical region, which is an essential differential diagnosis from PG 20,21 . The papules can converge, forming plaques and extending to the limbs, trunk, and buttocks, protecting the mucous membranes and face (Figure 1). They may exhibit small vesicles, target lesions, and polycyclic papules 14,22 . Generally, the condition persists for 4–6 weeks 4 .

Figure 1. Polymorphic eruption of pregnancy with erythematous-urticarial papules accompanying the striae (forming fibrous cords) and sometimes going beyond the striae and forming plaques in the abdominal region, always sparing the periumbilical region. Confluent papules form plaques in the region of the thighs. Source: High Risk Prenatal Service (PNAR) at the Clinical Hospital at the Federal University of Minas Gerais.

Figure 1

The diagnosis is clinical, with nonspecific histopathological examination and negative direct immunofluorescence (DIF) and indirect immunofluorescence (IIF) 10 .

Therapy involves psychological support, clarification of doubts, and symptom treatment: use of comfortable cotton clothes, body moisturizers, and low or moderate-potency corticosteroid cream, in addition to topical antipruritics, such as water paste. Refractory cases can be treated with low-dose oral corticosteroids. There is a regression in weeks after delivery, and, in the authors’ experience, a significant improvement is observed within a few hours after delivery 13,15,22 . PEP does not affect maternal and fetal prognosis, and there are no reports of recurrence in subsequent pregnancies 4 .

PEMPHIGOID GESTATIONIS

Bunel recognized PG in 1811, and Milton reported it in 1872, naming it Herpes gestationis 1 . It is a rare, pruritic autoimmune bullous disease with clinical and pathological features similar to bullous pemphigoid (BP). Its incidence varies from around 1:50,000 to 1:60,000 pregnancies, and it is more common in multiparous women 23,24 .

Autoantibodies of the IgG class form the skin lesions. These antibodies are formed against the NC16a domain of BP 180 transmembrane antigen, currently known as collagen XVII, located in the skin basement membrane zone (BMZ) and chorionic amniotic epithelia 21,24 . PG is associated with the abnormal expression of MHCII antigens HLA-B8, DR3, and DR4 24 .

PG manifests commonly in the second and third trimesters of pregnancy (between 21 and 28 weeks) and, rarely, postpartum 20,21,24,25 . It usually recurs in future pregnancies, starting earlier and with a more severe presentation 7,24,25 . Also, it can relapse with menstruation and during the use of oral contraceptives 18,2326 . The literature has reported PG associated with trophoblastic tumors such as hydatidiform mole and choriocarcinoma 7,24 . The risks for the fetus are prematurity, low birth weight, and, rarely, a bullous eruption due to transplacental passage of maternal antibodies (<10%), with rapid and spontaneous resolution in most cases 14,21,24,26 .

Clinically, there is an initial phase in which erythematous and urticarial papules and plaques predominate, followed by vesicles and blisters. Itching is intense and can be disabling 23 . In 90% of the cases, the lesions are initially located in the periumbilical region and spread to the abdomen and limbs 20,21,23,24 . The oral mucosa is rarely affected (15–20%) 26 . The primary differential diagnosis is PEP, where immunofluorescence studies are negative and generally spare the periumbilical region 20,21 . PG can be associated with other autoimmune diseases 23 .

Histopathological examination of the initial lesions shows papillary edema with lymphocyte infiltration and a variable number of eosinophils in the dermis 24,25 . The histopathological pattern of a recent, intact blister is that of a subepidermal cleavage without acantholysis 26 . DIF of perilesional skin biopsies reveals linear deposition of C3 in approximately 30% of cases of IgG along the BMZ 20,21,2426 . IIF in patient serum can be positive in most cases, and immunoblotting studies show that 90% of serum from patients with PG recognizes collagen XVII 21,24 . Detection of the NC16A domain of collagen XVII by ELISA has a sensitivity and specificity of 96% 21,26 . It is directly related to disease activity and helps differentiate PG from other pruritic dermatoses of pregnancy, including PEP 21 . It should also be differentiated from other bullous dermatoses, drug reactions, and erythema multiforme 27 .

Mild cases with localized lesions are treated with low- to medium-potency topical corticosteroids and local skin care 2326 . For patients with severe disease, therapy is based on systemic corticosteroid therapy 23,24 . The only criterion proposed in the literature to differentiate between mild and severe forms is the affected body surface area (< or>10%). There may be a worsening in the immediate postpartum period that may require an increase in medication dose. The drug should be discontinued 2 weeks after delivery withdrawing in 3–6 months, depending on the severity and progression of lesions 24,26 . The involvement of the multidisciplinary team is encouraged in approaching the diagnosis and management of this condition 14 .

ATOPIC ERUPTION OF PREGNANCY

AEP, a term proposed by Ambros-Rudolph et al. in 2006 8 , encompasses clinical conditions of atopic dermatitis that exacerbate or appear during pregnancy 4 . This dermatosis is often idiopathic, and its pathogenesis has not been fully understood. Its clinical manifestations have an earlier onset (first and second trimester of pregnancy) than the other SDP 4 . However, patients without an atopic history are more likely to have a later onset of the disease 11 .

Ambros-Rudolph et al. described two clinical presentations: the eczematous type (E-type) with a classic distribution of lesions, including eczematous eruption on the face, neck, pre-sternal region, and flexors, and the prurigo type (P-type) with the presence of small, pruritic, erythematous papules, often clustered, disseminated predominantly on extensor surfaces of extremities and trunk 8 . IgE measurement has not been systematically studied in pregnancy, and its role as a diagnostic criterion is unclear 4 .

There are controversies about including PFP and PP in AEP. Some authors consider them to be separate entities 913,15 . PFP, described in 1981 by Zoberman and Famer, constitutes an erythematous papular, monomorphic eruption found in the second and third trimesters of pregnancy 28 with spontaneous regression after delivery 12 . A prospective study found 0.03% of cases consistent with PFP in 3,192 pregnant women followed up 14,29 . PP, formerly known as Besnier's prurigo gestationis and early pregnancy prurigo, begins around the 25th to 30th weeks of gestation as pruritic and erythematous papules and nodules in the extensor regions of the extremities and trunk 30 .

Regardless of the clinical manifestation and classification, the treatment of this group of SDP is symptomatic 12 . They regress after delivery and do not affect maternal-fetal health 30 .

INTRAHEPATIC CHOLESTASIS OF PREGNANCY

IHCP, described by Kehrer in 1907 as recurrent jaundice of pregnancy 1 , has several names: cholestasis of pregnancy, prurigo gravidarum, and pruritus of pregnancy 13,15 . It is the only SDP that initially presents with pruritus without primary cutaneous lesions. Its prevalence ranges between 0.3 and 5.6% of pregnancies, depending on geographic and ethnic factors. A large study in Australia found a prevalence of 0.7% 14,31 . The family history is positive in 50% of the cases, and it is more frequent in twin pregnancies 1 . It occurs at the beginning of the second or third trimester of pregnancy, but there are reports of early onset, around the 8th week of pregnancy. IHCP may recur in subsequent pregnancies in 70% of cases and with the use of oral contraceptives 14,18,32 .

IHCP pathogenesis is multifactorial and not fully understood. It is believed that genetic, hormonal, immunological, and environmental factors may contribute and that the estrogen-bile acid axis plays a dominant role. Also, extracellular matrix and oxygen supply deregulation, organelle dysfunction, and epigenetic alterations may occur 33 .

Clinically, it is characterized by intense, persistent, and generalized skin itching, which almost always gets worse at night and, at first, can be located only on the palmar and plantar region. Excoriations, erosions, and small papules are often secondary to scratching (Figure 2) 14 . Jaundice occurs in less than 20% of cases, and choluria and acholic stools may occur in 50% of cases, usually 2–4 weeks after the onset of pruritus 1 .

Figure 2. Pregnant woman with severe intrahepatic cholestasis of pregnancy, starting in the second trimester: excoriations, erosions, and residual hyperchromia throughout the integument secondary to scratching. Source: High Risk Prenatal Service (PNAR) at the Clinical Hospital at the Federal University of Minas Gerais.

Figure 2

There is no consensus on diagnostic criteria: some entities use persistent pruritus that disappears after delivery with bile acid concentration >10 μmol/L 33 . Liver enzymes, such as ALT, AST, and ALP, may be slightly elevated. Other causes of liver dysfunction must be ruled out 34 .

The treatment of choice is ursodeoxycholic acid (UDCA) at 10–15 mg/kg/day to control itching and reduce bile acid levels 32 . Although UDCA is also used to improve fetal outcomes, there is controversy about its effect 33,34 . Emollients, topical antipruritic agents, and antihistamines are ineffective. In cases of prolonged cholestasis, administration of vitamin K may be necessary 35 . Pruritus usually resolves within 48 hours after delivery, and laboratory tests resolve within 2–4 weeks 30 .

Maternal prognosis is usually favorable, and fetal risks are prematurity, perinatal mortality, and fetal distress. In a meta-analysis, Ovadia et al. provided evidence that IHCP is associated with a significantly increased risk of stillbirth for women with total serum bile acids of 100 μmol/L or higher. This study reinforces the inclusion of serum bile acid measurement in the diagnostic criteria for IHCP and recommends its wide use and monitoring during pregnancy 36 .

The advances in the last 10 years regarding pathogenesis can bring potential targets for our drugs 33 . Intensive maternal and fetal monitoring is recommended, in addition to follow-up by an experienced multidisciplinary team to help decide the exact and safest moment for delivery 35 .

FINAL CONSIDERATIONS

In SDP, the diagnosis is mainly based on clinical findings. Aside from PG and IHCP, no laboratory method is sufficient to differentiate these dermatoses, making clinical observation essential and leaving laboratory analysis for the differential diagnosis. Thus, the itching symptom should never be neglected, especially after the second and third trimesters of pregnancy. It affects the quality of life of the pregnant woman and can be a sign of several diseases.

Future elucidations of the etiology and pathophysiology of SDP will possibly bring new therapeutic modalities. Monitoring by a multidisciplinary team involving obstetricians, dermatologists, and other health professionals is encouraged in approaching the diagnosis and management of these conditions. The ultimate goal is optimal quality prenatal care for the pregnant woman and the fetus, with clinical monitoring and risk-benefit assessment on an individual basis.

Footnotes

Funding: none.

Brazilian Society of Dermatology

REFERENCES

  • 1.Al-Fares SI, Jones SV, Black MM. The specific dermatoses of pregnancy: a re-appraisal. J Eur Acad Dermatol Venereol. 2001;15(3):197–206. doi: 10.1046/j.1468-3083.2001.00209.x. [DOI] [PubMed] [Google Scholar]
  • 2.Sharma A, Jharaik H, Sharma R, Chauhan S, Wadhwa D. Clinical study of pregnancy associated cutaneous changes. Int J Clin Obst Gynaecol. 2019;3(4):71–75. doi: 10.33545/gynae.2019.v3.i4b.292. [DOI] [Google Scholar]
  • 3.Putra IB, Jusuf NK, Dewi NK. Skin changes and safety profile of topical products during pregnancy. J Clin Aesthet Dermatol. 2022;15(2):49–57. [PMC free article] [PubMed] [Google Scholar]
  • 4.Stefaniak AA, Pereira MP, Zeidler C, Ständer S. Pruritus in pregnancy. Am J Clin Dermatol. 2022;23(2):231–246. doi: 10.1007/s40257-021-00668-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ambros-Rudolph CM, Black MM. In: Obstetric and gynecologic dermatology. 3rd ed. Black M, Ambros-Rudolph CM, Edwards L, Lynch PJ, editors. London: Mosby-Elsevier; 2008. A systematic approach to the dematoses of pregnancy; pp. 31–36. [Google Scholar]
  • 6.Holmes RC, Black MM. The specific dermatoses of pregnancy: a reappraisal with special emphasis on a proposed simplified clinical classification. Clin Exp Dermatol. 1982;7(1):65–73. doi: 10.1111/j.1365-2230.1982.tb02387.x. [DOI] [PubMed] [Google Scholar]
  • 7.Holmes RC, Black MM. The specific dermatoses of pregnancy. J Am Acad Dermatol. 1983;8(3):405–412. doi: 10.1016/s0190-9622(83)70046-0. [DOI] [PubMed] [Google Scholar]
  • 8.Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol. 2006;54(3):395–404. doi: 10.1016/j.jaad.2005.12.012. [DOI] [PubMed] [Google Scholar]
  • 9.Kroumpouzos G. Prurigo of pregnancy: an appropriate term for cases not associated with atopy. Obstet Med. 2021;14(3):197–197. doi: 10.1177/1753495X211029127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rudder M, Lefkowitz EG, Firoz E. What's in a name? Prurigo versus atopic eruption of pregnancy without atopic history. Obstet Med. 2021;14(3):198–198. doi: 10.1177/1753495X211029131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ravelli FN, Goldust M, Kroumpouzos G. Assessment of prurigo of pregnancy in patients without atopic background. Int J Womens Dermatol. 2020;6(5):384–389. doi: 10.1016/j.ijwd.2020.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Carvalho MLRC, Alves GF, Azulay-Abulafia L. In: Dermatologia e gravidez. Costa A, Azulay-Abulafia L, editors. Rio de Janeiro: Elsevier; 2009. Dermatoses específicas da gravidez; pp. 175–185. [Google Scholar]
  • 13.Carvalho MLR, Leite HV. In: Ginecologia e obstetrícia - assistência primária e saúde da família. Falcão JOA Júnior, Barra JS, Armond SC, Rodrigues MAH, editors. Rio de Janeiro: MedBook - Editora Científica Ltda; 2017. Dermopatias e gravidez; pp. 185–199. [Google Scholar]
  • 14.Ting S, Nixon R. Assessment and management of itchy skin in pregnancy. Aust J Gen Pract. 2021;50(12):898–903. doi: 10.31128/AJGP-03-21-5900. [DOI] [PubMed] [Google Scholar]
  • 15.Carvalho MLR, Péret LA. In: Manual SOGIMIG de ginecologia e obstetrícia. 6th ed. Silva AL Filho, Laranjeira CLS, editors. Rio de Janeiro: MedBook - Editora Científica Ltda; 2017. Alterações cutâneas na gravidez; pp. 882–889. [Google Scholar]
  • 16.Ishikawa-Nishimura M, Kondo M, Matsushima Y, Habe K, Yamanaka K. A Case of pruritic urticarial papules and plaques of pregnancy: pathophysiology and serum cytokine profile. Case Rep Dermatol. 2021;13(1):18–22. doi: 10.1159/000511494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bohdanowicz M, Ghazarian D, Rosen CF. Targetoid form of polymorphic eruption of pregnancy: a case report. SAGE Open Med Case Rep. 2019;7 doi: 10.1177/2050313X19882841. 2050313X19882841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kroumpouzos G, Cohen LM. Specific dermatoses of pregnancy: an evidence-based systematic review. Am J Obstet Gynecol. 2003;188(4):1083–1092. doi: 10.1067/mob.2003.129. [DOI] [PubMed] [Google Scholar]
  • 19.Dokuzeylul Gungor N, Gurbuz T, Ture T. Prolonged luteal phase support with progesterone may increase papules and plaques of pregnancy frequency in pregnancies through in vitro fertilization. An Bras Dermatol. 2021;96(2):171–175. doi: 10.1016/j.abd.2020.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Miyagawa F, Arima A, Iwasa K, Ishii N, Hashimoto T, Asada H. Postpartum pruritic urticarial papules and plaques of pregnancy with blister formation resembling herpes gestationis. Eur J Dermatol. 2019;29(6):669–671. doi: 10.1684/ejd.2019.3669. [DOI] [PubMed] [Google Scholar]
  • 21.Powell AM, Sakuma-Oyama Y, Oyama N, Albert S, Bhogal B, Kaneko F, et al. Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy. Arch Dermatol. 2005;141(6):705–710. doi: 10.1001/archderm.141.6.705. [DOI] [PubMed] [Google Scholar]
  • 22.Mehedintu C, Isopescu F, Ionescu OM, Petca A, Bratila E, Cirstoiu MM, et al. Diagnostic pitfall in atypical febrile presentation in a patient with a pregnancy-specific dermatosis-case report and literature review. Medicina (Kaunas) 2022;58(7):847–847. doi: 10.3390/medicina58070847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ceryn J, Siekierko A, Skibińska M, Doss N, Narbutt J, Lesiak A. Pemphigoid gestationis - case report and review of literature. Clin Cosmet Investig Dermatol. 2021;14:665–670. doi: 10.2147/CCID.S297520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cohen S, Strowd LC, Pichardo RO. Pemphigoid gestationis: a case series and review of the literature. J Dermatolog Treat. 2018;29(8):815–818. doi: 10.1080/09546634.2018.1459034. [DOI] [PubMed] [Google Scholar]
  • 25.Snarskaya ES, Olisova OY, Makatsariya AD, Kochergin NG, Radetskaya L, Bitsadze V, et al. Skin pathologies in pregnancy. J Perinat Med. 2019;47(4):371–380. doi: 10.1515/jpm-2018-0338. [DOI] [PubMed] [Google Scholar]
  • 26.Ingen-Housz-Oro S, Bedane C, Prost C, Joly P, Bernard P. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie. Pemphigoid gestationis. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie. Ann Dermatol Venereol. 2011;138(3):264–266. doi: 10.1016/j.annder.2011.01.015. [DOI] [PubMed] [Google Scholar]
  • 27.Jenkins RE, Shornick J. In: Obstetric and gynecologic dermatology. 3rd ed. Black M, Ambros-Rudolph CM, Edwards L, Lynch PJ, editors. London: Mosby-Elsevier; 2008. Pemphigoid (herpes) gestationis; pp. 38–47. [Google Scholar]
  • 28.Zoberman E, Farmer ER. Pruritic folliculitis of pregnancy. Arch Dermatol. 1981;117(1):20–22. [PubMed] [Google Scholar]
  • 29.Roger D, Vaillant L, Fignon A, Pierre F, Bacq Y, Brechot JF, et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol. 1994;130(6):734–739. [PubMed] [Google Scholar]
  • 30.Schlosser BJ. In: Sinais dermatológicos das doenças sistêmicas. 5th ed. Callen JP, Jorizzo JL, Zone JJ, Piette WW, Rosenbach MA, Vleugels RA, editors. Rio de Janeiro: Elsevier Editora Ltda; 2018. Gravidez; pp. 359–369. [Google Scholar]
  • 31.Gardiner FW, McCuaig R, Arthur C, Carins T, Morton A, Laurie J, et al. The prevalence and pregnancy outcomes of intrahepatic cholestasis of pregnancy: a retrospective clinical audit review. Obstet Med. 2019;12(3):123–128. doi: 10.1177/1753495X18797749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol. 2018;231:180–187. doi: 10.1016/j.ejogrb.2018.10.041. [DOI] [PubMed] [Google Scholar]
  • 33.Xiao J, Li Z, Song Y, Sun Y, Shi H, Chen D, et al. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Can J Gastroenterol Hepatol. 2021;2021:6679322–6679322. doi: 10.1155/2021/6679322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wood AM, Livingston EG, Hughes BL, Kuller JA. Intrahepatic cholestasis of pregnancy: a review of diagnosis and management. Obstet Gynecol Surv. 2018;73(2):103–109. doi: 10.1097/OGX.0000000000000524. [DOI] [PubMed] [Google Scholar]
  • 35.Vaughan Jones SA, Black MM. Pregnancy dermatoses. J Am Acad Dermatol. 1999;40(2 Pt 1):233–241. doi: 10.1016/s0190-9622(99)70194-5. [DOI] [PubMed] [Google Scholar]
  • 36.Ovadia C, Seed PT, Sklavounos A, Geenes V, Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393(10174):899–909. doi: 10.1016/S0140-6736(18)31877-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Revista da Associação Médica Brasileira are provided here courtesy of Associação Médica Brasileira

RESOURCES